Multicomponent meningococcal vaccine
AssigneeSecretary of State for Health and Social Care
InventorsAndrew Robinson, Margaret Robinson, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin
Life of this patent
Estimating the term…
Abstract
A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.
Claims25
A composition comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component.
A vaccine composition comprising outer membrane vesicles from a first strain of N. meningitidis, as well as an antigenic component from a second strain of N. meningitidis different from the first, and a pharmaceutically acceptable carrier.
(canceled)
A method of manufacture of a composition, comprising:
- (a) extracting an antigenic component from an outer membrane of a bacteria, and preparing an aqueous solution of said antigenic component;
- (b) extracting outer membrane vesicles from a culture of N. meningitidis, and preparing an aqueous solution of said outer membrane vesicles;
- (c) obtaining a pharmaceutically acceptable carrier;
- and
- (d) admixing the solution prepared in (a), the solution prepared in (b) and the carrier obtained in (c).
-21. (canceled)
A method of manufacture of a composition, comprising:
- (a) recombinantly expressing a DNA that encodes an antigenic component in a bacteria;
- (b) extracting said antigenic component from the outer membrane of said bacteria, and preparing an aqueous solution of said antigenic component;
- (c) extracting outer membrane vesicles from a culture of N. meningitidis, and preparing an aqueous solution of said outer membrane vesicles;
- (d) obtaining a pharmaceutically acceptable carrier;
- and admixing the solution prepared in (b), the solution prepared in (c) and the carrier obtained in (d).
(canceled)
A method of manufacture of a composition, comprising:
- (a) recombinantly expressing a DNA that encodes an antigenic component in N. meningitidis;
- (b) extracting outer membrane vesicles from said N. meningitidis, and preparing an aqueous solution of said outer membrane vesicles, wherein said outer membrane vesicles comprise said antigenic component;
- (c) obtaining a pharmaceutically acceptable carrier;
- and
- (d) admixing the solution prepared in (b), with the carrier obtained in (c).
-27. (canceled)
A method of preventing N. meningitidis infection in an animal, comprising administering an effective dose of a composition comprising an outer membrane vesicle and an antigenic component selected from the group consisting of Cu,Zn-superoxide dismutase;
- neisserial surface protein A (NspA);
- porA;
- OMP85;
- FrpB;
- PiIQ;
- Hsf;
- HemK;
- sodC;
- mafA;
- N-acetyl glutamate synthetase;
- and macrophage infectivity potentiator-related protein, and a pharmaceutically acceptable carrier.
-31. (canceled)
A composition comprising isolated N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one isolated N. meningitidis antigenic protein,
- wherein the composition is obtained by a process comprising isolating said at least one N. meningitidis antigenic protein and combining the isolated outer membrane vesicles with the at least one isolated N. meningitidis antigenic protein, and
- said N. meningitidis antigenic protein is an N. meningitidis antigenic proteoglycan.
A composition comprising isolated N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one isolated N. meningitidis antigenic protein,
- wherein the composition is obtained by a process comprising isolating said at least one N. meningitidis antigenic protein and combining the isolated outer membrane vesicles with the at least one isolated N. meningitidis antigenic protein, and
- the composition further comprises Haemophilus surface fibril (Hsf).
A vaccine composition comprising isolated outer membrane vesicles from a first strain of N. meningitidis, an isolated N. meningitidis antigenic protein from a second strain of N. meningitidis different from the first, Haemophilus surface fibril (Hsf), and a pharmaceutically acceptable carrier.
A composition comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with porA.
Dependencies are inferred from the claim text.